CN1259934C - 一种用于治疗心血管疾病的山楂叶注射剂 - Google Patents
一种用于治疗心血管疾病的山楂叶注射剂 Download PDFInfo
- Publication number
- CN1259934C CN1259934C CN 03102024 CN03102024A CN1259934C CN 1259934 C CN1259934 C CN 1259934C CN 03102024 CN03102024 CN 03102024 CN 03102024 A CN03102024 A CN 03102024A CN 1259934 C CN1259934 C CN 1259934C
- Authority
- CN
- China
- Prior art keywords
- injection
- folium crataegi
- extract
- medicine
- cardiovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002347 injection Methods 0.000 title claims abstract description 63
- 239000007924 injection Substances 0.000 title claims abstract description 63
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 24
- 239000002904 solvent Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- ZIIBNXKQZAUBRD-VVZHCWMZSA-N Vitexin rhamnoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC=C(C=2OC3=C([C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C(O)=CC(O)=C3C(=O)C=2)C=C1 ZIIBNXKQZAUBRD-VVZHCWMZSA-N 0.000 claims description 22
- 229930003944 flavone Natural products 0.000 claims description 21
- 235000011949 flavones Nutrition 0.000 claims description 21
- 150000002213 flavones Chemical class 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 9
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- NDSUKTASTPEKBX-LXXMDOISSA-N Vitexin glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](C=2C3=C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)C(O)=CC=2O)O[C@@H]1CO NDSUKTASTPEKBX-LXXMDOISSA-N 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- FOGVNFMUZXDMTR-UHFFFAOYSA-N [Mg].Cl Chemical compound [Mg].Cl FOGVNFMUZXDMTR-UHFFFAOYSA-N 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- -1 lower floor filters Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 2
- 150000002212 flavone derivatives Chemical class 0.000 claims description 2
- 239000012155 injection solvent Substances 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 37
- 229910052760 oxygen Inorganic materials 0.000 abstract description 37
- 239000001301 oxygen Substances 0.000 abstract description 37
- 230000000747 cardiac effect Effects 0.000 abstract description 20
- 230000036284 oxygen consumption Effects 0.000 abstract description 13
- 230000002107 myocardial effect Effects 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000036770 blood supply Effects 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 66
- 241000282472 Canis lupus familiaris Species 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 11
- 230000036581 peripheral resistance Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000003748 coronary sinus Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000003182 parenteral nutrition solution Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 230000005622 photoelectricity Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 剂量/kg | 药前值变化率 | 药中5min | 药后即刻 | 药后(min) | |||
1 | 3 | 5 | 10 | |||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 1.108±0.3521.421±0.5031.145±0.223 | 1.113±0.361100.31±3.741.507±0.529##106.26±4.61**1.143±0.631100.10±46.75 | 1.095±0.37598.04±7.381.550±0.499##110.38±11.50*1.187±0.189#104.37±5.70* | 1.094±0.38997.63±6.451.548±0.499#110.32±12.61*1.183±0.215103.80±6.90* | 1.066±0.41094.37±13.751.580±0.498##112.82±15.40*1.193±0.251##104.00±4.55*** | 1.078±0.40095.86±14.401.603±0.525##114.12±13.64*1.188±0.213104.33±8.08* | 1.084±0.34697.77±4.021.618±0.505##115.97±14.52***1.217±0.175#107.71±13.49 |
组别 | 剂量/kg | 药后(min) | |||||
15 | 30 | 45 | 60 | 90(n=6) | 120(n=6) | ||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 1.098±0.35199.00±4.861.613±0.529##115.08±15.19**1.230±0.263#107.61±9.07* | 1.083±0.35897.20±6.391.557±0.510#111.35±15.16*1.167±0.272102.11±16.75 | 1.062±0.340#95.61±7.761.483±0.524105.60±15.261.112±0.29097.15±19.89 | 1.084±0.34097.88±6.671.428±0.528101.42±13.721.058±0.24392.88±16.32 | 1.062±0.335#89.84±10.941.645±0.556100.91±17.330.902±0.168##79.61±12.19 | 1.068±0.348#90.15±12.191.598±0.61097.23±19.010.873±0.17476.78±11.90* |
组别 | 剂量/kg | 药前值变化率 | 药中5min | 药后即刻 | 药后(min) | |||
1 | 3 | 5 | 10 | |||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 6.303±1.7828.243±2.9138.759±0.982 | 6.397±1.930101.01±5.998.930±3.107###109.05±4.97**8.988±1.139102.97±11.24 | 6.313±2.03199.29±11.349.178±2.967###112.91±10.17*9.140±1.575104.58±14.79 | 6.293±2.06798.68±8.889.173±3.154##112.26±12.02*9.102±1.158104.40±12.53 | 6.159±2.23195.90±17.109.281±3.138##113.65±15.56*9.105±1.242104.27±11.38 | 6.287±2.13698.59±18.799.444±3.279##115.41±14.51*9.175±1.565104.80±12.94 | 6.295±1.784100.01±10.099.553±3.261##117.55±15.28**9.353±1.748106.85±15.88** |
组别 | 剂量/kg | 药后(min) | |||||
15 | 30 | 45 | 60 | 90(n=6) | 120(n=6) | ||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 6.349±1.884100.51±10.049.477±3.138##116.59±15.71*9.505±1.762108.89±17.63 | 6.189±1.92097.43±8.909.286±3.266#114.19±16.20*9.178±1.732105.47±19.99 | 6.117±1.81296.65±9.558.778±3.453107.12±15.598.834±1.742101.33±18.73 | 6.215±1.76098.67±9.018.445±3.452102.59±13.038.274±1.59094.91±16.87 | 5.793±893##88.18±12.039.729±4.004102.69±17.597.918±1.94590.72±20.07 | 5.857±836##89.41±10.549.456±4.37399.07±21.277.487±1.799#85.92±19.28 |
组别 | 剂量/kg | 药前值变化率 | 药中5min | 药后即刻 | 药后(min) | |||
1 | 3 | 5 | 10 | |||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 10572.4±2747.49508.7±2975.89170.8±1353.5 | 10472.4±2776.999.26±6.658786.6±3014.0###91.78±5.10*9058.7±1416.799.14±9.93 | 10840.5±3153.4102.12±8.118645.5±2872.5#91.17±8.47*9263.7±1869.9101.27±15.51 | 10861.0±3153.6102.17±6.858603.6±2756.4##90.96±7.98**9346.9±1721.2102.31±14.43 | 11788.8±5555.6108.88±24.298450.9±2978.1#88.93±9.56*9533.5±1754.1104.22±14.06 | 11653.3±5982.7107.23±27.958296.0±2751.7###87.32±7.22*9627.0±1653.8105.15±11.46 | 10799.5±2799.7102.38±4.498242.9±2785.5###86.50±6.91***9691.4±1425.5#105.97±8.16 |
组别 | 剂量/kg | 药后(min) | |||||
15 | 30 | 45 | 60 | 90(n=6) | 120(n=6) | ||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 10505.5±2803.099.47±5.948309.4±2904.9###86.89±8.07***9192.6±1000.6101.07±9.04 | 11106.6±3580.8104.03±9.028439.9±2939.0###88.20±8.26***9197.2±972.6102.05±17.66 | 11319.7±3489.0#106.27±8.938995.7±3239.793.60±9.82*9345.6±1258.0103.65±19.41 | 10851.6±3414.6101.52±6.699389.3±3504.297.52±13.829769.0±1176.1108.09±17.18 | 10744.0±2928.8102.87±6.077499.2±2335.296.99±17.1510601.5±1539.7117.44±21.58 | 10612.4±3112.5101.17±6.297795.0±2569.6101.02±21.2311370.4±1830.0126.49±28.07* |
组别 | 剂量/kg | 药前值变化率 | 药后即刻 | 药后(min) | |||||
5 | 15 | 30 | 60 | 90(n=6) | 120(n=6) | ||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 11.41±2.9711.88±1.827.67±2.72 | 11.33±2.9799.41±5.4110.94±1.72#92.44±8.01*7.80±2.38104.03±10.34 | 11.31±2.8699.55±4.6311.48±1.9196.71±7.227.90±2.31105.99±12.58 | 11.50±3.01101.10±5.8011.65±1.9798.17±8.477.85±2.15105.38±11.14 | 11.42±2.89100.39±4.7911.66±1.9998.30±9.177.88±2.41104.64±7.44 | 11.20±3.0498.29±7.4311.82±2.2599.44±11.037.60±2.42100.41±7.86 | 9.52±2.69100.80±8.5712.12±2.46102.16±14.857.60±2.15101.54±10.34 | 9.62±3.13100.99±12.3611.98±2.36101.37±16.937.55±2.3199.89±6.02 |
组别 | 剂量/kg | 药前值变化率 | 药后即刻 | 药后(min) | |||||
5 | 15 | 30 | 60 | 90(n=6) | 120(n=6) | ||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 5.59±3.122.78±1.352.35±1.21 | 5.37±2.91100.34±14.963.67±2.12##127.62±24.13*2.82±1.10138.21±63.99 | 5.26±2.7897.84±12.883.98±1.89###147.93±34.06***2.92±1.81131.86±74.26 | 5.19±2.96#94.66±11.674.08±1.7###153.36±26.62***3.18±2.34144.09±102.97 | 5.10±3.04#91.97±21.054.37±1.77###168.91±45.85***3.28±2.41147.15±103.89 | 5.08±2.93##91.80±16.614.13±1.77##157.51±48.32***3.27±2.55146.68±109.91 | 2.22±1.12#85.29±30.373.77±1.80##167.07±61.5O*3.10±2.10135.77±83.92 | 240±1.4988.02±30.583.88±1.72##180.93±68.89*2.95±2.090130.74±88.58 |
组别 | 剂量/kg | 药前值变化率 | 药后即刻 | 药后(min) | |||||
5 | 15 | 30 | 60 | 90(n=6) | 120(n=6) | ||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml10mg10mg | 5.19±2.368.44±2.325.50±2.62 | 5.29±2.51101.36±7.546.86±2.22#82.21±19.86*5.12±1.16100.70±23.56 | 5.37±2.31104.31±7.477.23±1.89#86.86±16.92*5.32±1.31107.07±35.72 | 5.56±2.79105.29±8.407.22±2.03#86.39±18.37*5.27±1.79111.18±46.08 | 5.44±2.62104.13±12.436.80±1.59##81.97±12.50***5.06±1.37105.31±40.27 | 5.19±2.39100.15±7.727.05±1.76##84.85±14.95*4.59±1.3997.08±37.93 | 5.69±2.48101.00±11.497.94±1.4689.92±21.474.70±1.2599.27±42.55 | 5.61±2.5798.83±14.047.26±1.0582.44±18.614.98±1.13106.52±43.93 |
组别 | 剂量/kg | 药前值变化率 | 药后即刻 | 药后(min) | |||||
5 | 15 | 30 | 60 | 90(n=6) | 120(n=6) | ||||
生理盐水(n=12)本发明注射液(n=12)益心酮(n=6) | 1ml1mg10mg | 38.10±6.8674.74±9.2869.95±11.84 | 54.88±18.06103.34±11.5967.37±17.16##86.21±15.00*64.72±6.9694.29±14.94 | 55.99±17.67105.83±11.3265.89±13.63###84.78±9.48***65.63±13.7694.80±17.26 | 57.23±19.25#107.24±11.8265.31±13.19###84.16±10.08***63.05±18.5892.02±26.58 | 57.81±20.07108.31±12.6962.82±13.00###81.10±11.47***62.40±17.5890.87±24.88 | 57.57±19.06#107.99±8.3965.15±13.67##84.22±12.52***61.41±19.9189.55±28.52 | 77.33±6.80108.69±11.8869.65±12.86#86.87±11.18*62.75±17.6390.86±23.44 | 76.58±7.68107.33±9.7468.04±11.87##84.96±11.08**64.59±16.6994.32±25.16 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03102024 CN1259934C (zh) | 2003-01-28 | 2003-01-28 | 一种用于治疗心血管疾病的山楂叶注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03102024 CN1259934C (zh) | 2003-01-28 | 2003-01-28 | 一种用于治疗心血管疾病的山楂叶注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1520832A CN1520832A (zh) | 2004-08-18 |
CN1259934C true CN1259934C (zh) | 2006-06-21 |
Family
ID=34281553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03102024 Expired - Lifetime CN1259934C (zh) | 2003-01-28 | 2003-01-28 | 一种用于治疗心血管疾病的山楂叶注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1259934C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920727A (zh) * | 2012-11-09 | 2013-02-13 | 苏州衷中医药科技有限公司 | 制备富含牡荆素鼠李糖苷和牡荆素葡萄糖苷提取物的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1839957B (zh) * | 2006-01-24 | 2010-06-23 | 上海玉森新药开发有限公司 | 一种聚酰胺柱提取注射用山楂叶总黄酮原料的方法 |
-
2003
- 2003-01-28 CN CN 03102024 patent/CN1259934C/zh not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920727A (zh) * | 2012-11-09 | 2013-02-13 | 苏州衷中医药科技有限公司 | 制备富含牡荆素鼠李糖苷和牡荆素葡萄糖苷提取物的方法 |
CN102920727B (zh) * | 2012-11-09 | 2014-10-22 | 苏州衷中医药科技有限公司 | 制备富含牡荆素鼠李糖苷和牡荆素葡萄糖苷提取物的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1520832A (zh) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1931236B (zh) | 一种由丹参和红景天制成的药物组合物 | |
CN101033245A (zh) | 具栖冬青苷的制备方法及应用 | |
CN1726956A (zh) | 葛根总黄酮提取物及其制备方法和应用 | |
CN1224383C (zh) | 一类新型降低血糖化合物 | |
CN1771944A (zh) | 高溶解度黄连素在制药中的应用 | |
CN101040906A (zh) | 一种治疗心脑血管疾病的注射剂及其制备方法和质控方法 | |
CN1259934C (zh) | 一种用于治疗心血管疾病的山楂叶注射剂 | |
CN101028328A (zh) | 柿叶提取物的制备及应用 | |
CN1850167A (zh) | 一种消渴降糖滴丸及其制备方法 | |
CN1846734A (zh) | 水红花制剂和制备方法及其应用 | |
CN1264506C (zh) | 一种丹参素的药物组合物的制备方法 | |
CN101028387A (zh) | 一种治疗慢性前列腺炎的口服固体制剂及其制备方法 | |
CN1081465C (zh) | 一种治疗冠心病心绞痛的红景天注射剂的制备方法 | |
CN1468860A (zh) | 刺五加总皂苷提取物及其药物组合物 | |
CN1872101A (zh) | 具抗病毒作用的小紫金牛提取物及其提取方法和应用 | |
CN1268319C (zh) | 一种圣地红景天注射液制剂及其制备方法 | |
CN1899410A (zh) | 一种治疗心血管疾病的药物及其制备方法质量控制方法 | |
CN101073598A (zh) | 一种治疗心脑血管病的药物组合物及其制剂 | |
CN1813885A (zh) | 复方丹参喷雾剂及其制备方法 | |
CN1229127C (zh) | 一种防治高血压的药物组合物及其质量控制方法和用途 | |
CN1234370C (zh) | 一种治疗心血管疾病和休克急救的中药注射剂 | |
CN1615956A (zh) | 人参四逆注射剂及制备方法 | |
CN1552723A (zh) | 辽东楤木叶总皂苷及其药物组合物 | |
CN1689593A (zh) | 一种注射用参附粉针剂的制备方法 | |
CN1251717C (zh) | 一种治疗冠心病心绞痛的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SHINEWAY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHIJIAZHUANG SHINEWAY PHARMACEUTICAL CO., LTD. Effective date: 20040813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040813 Address after: The south of Luancheng County of Hebei city in Shijiazhuang Province Applicant after: SHINEWAY PHARMACEUTICAL Co.,Ltd. Address before: Shijiazhuang Hebei County of Luancheng Province pharmaceutical Limited by Share Ltd Applicant before: Shijiazhuang Shineway Pharmaceutical Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHINEWAY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHIJIAZHUANG SHINEWAY PHARMACEUTICAL CO., LTD. Effective date: 20040917 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040917 Address after: The south of Luancheng County of Hebei city in Shijiazhuang Province Applicant after: SHINEWAY PHARMACEUTICAL Co.,Ltd. Address before: The south of Luancheng County of Hebei city in Shijiazhuang Province Applicant before: Shijiazhuang Shineway Pharmaceutical Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HEBEI SHINEWAY PHARMACEUTICAL Co.,Ltd. Assignor: SHINEWAY PHARMACEUTICAL Co.,Ltd. Contract fulfillment period: 2008.12.20 to 2013.12.20 Contract record no.: 2009130000015 Denomination of invention: Haw leaf injection for treating cardiovascular disease Granted publication date: 20060621 License type: Exclusive license Record date: 20090219 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.12.20 TO 2013.12.20; CHANGE OF CONTRACT Name of requester: HEBEI SHINEWAY PHARMACEUTICAL CO., LTD. Effective date: 20090219 |
|
C56 | Change in the name or address of the patentee |
Owner name: SHINEWAY PHARMACEUTICAL GROUP LIMITED Free format text: FORMER NAME: SHINEWAY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: South Luancheng County 051430 Hebei city of Shijiazhuang Province Patentee after: SHINEWAY PHARMACEUTICAL Group Ltd. Address before: South Luancheng County 051430 Hebei city of Shijiazhuang Province Patentee before: SHINEWAY PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060621 |